Tuesday, September 27, 2011 10:24:58 AM
Sinovac's Animal Rabies Vaccine RabEnd Receives Production License
Date : 09/27/2011 @ 8:00AM
Source : PR Newswire
Stock : Sinovac Biotech, Ltd. (MM) (SVA)
Quote : 2.48 0.13 (5.53%) @ 10:05AM
Sinovac's Animal Rabies Vaccine RabEnd Receives Production License
Sinovac Biotech, Ltd. (MM) (NASDAQ:SVA)
Intraday Stock Chart
Today : Tuesday 27 September 2011
Click Here for more Sinovac Biotech, Ltd. (MM) Charts.
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that Tangshan Yian Biological Engineering Co., Ltd., its wholly owned subsidiary, received the production license for its developed inactivated animal rabies vaccine RabEnd from China's Ministry of Agriculture (MOA).
Tangshan Yian received the production license for its inactivated animal rabies vaccine on September 22, 2011 and previously obtained the New Animal Drug Certificate and the Certificate of Good Manufacturing Practices for Animal Drugs (GMP Certificate) from the Ministry of Agriculture. According to the Requirements of Chinese Good Manufacturing Practices for Animal Drugs, the production facility for animal vaccines at Tangshan Yian can be used to manufacture different inactivated animal vaccines with the similar production processes, which can yield cost savings and shorten launch schedules for subsequent products.
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "Receiving the production license for our animal rabies vaccines is a significant milestone as it represents the final step in the regulatory process before we launch this vaccine in China. Our inactivated vaccine, which is manufactured based on the local occurring rabies virus strain, provides pet owners in China with an inactivated animal rabies vaccine with improved effectiveness and competitive quality. Leveraging our ten years of human vaccine development, production and commercialization expertise, we are replicating our quality control systems and quality standards in animal vaccines. We have established a dedicated sales force and are teaming up with distributors to make this first China developed and manufactured inactivated animal rabies vaccine available to pet owners through the animal CDC's and veterinary hospitals."
About Animal Rabies
Rabies is a zoonotic disease (a disease that is transmitted to humans from animals) that is caused by a virus. The disease infects domestic and wild animals, and is spread to people through close contact with infected saliva via bites or scratches. Animal vaccination is the most effective strategy for reducing the incidence of rabies in humans by lowering human contact with rabid animals. On January 18, 2008, China's Ministry of Agriculture and Ministry of Health approved compulsory vaccination for dogs. Based on the estimation of the industry expert, there are about 80 million to 200 million dogs in China, which represents the potential of the market.
Rabies in China
China is one of the countries most threatened by rabies. Based on available data, approximately 2400 fatal human cases of rabies are reported each year China. Rabies is a vaccine-preventable disease and spending in China on human immunization has increased in recent years. According to the WHO, dogs cause 99% of human rabies deaths and the infection source can be controlled. The most cost effective strategy for preventing human rabies is to eliminate canine rabies through vaccination.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its developed inactivated rabies vaccine in China.
Recent SVA News
- SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F • Business Wire • 04/29/2024 09:53:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 02/21/2024 11:09:13 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 11:02:10 AM
- Sinovac Amends Shareholder Rights Plan • Business Wire • 02/21/2024 07:56:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/02/2024 04:19:55 PM
- シノバック取締役会、一方的な部分公開買い付けを全会一致で退ける • Business Wire • 01/19/2024 11:58:00 AM
- Sinovac董事會一致反對Alternative Liquidity主動提出的部分公開收購方案 • Business Wire • 01/18/2024 07:54:00 PM
- Le conseil d'administration de Sinovac rejette à l'unanimité une offre partielle non sollicitée • Business Wire • 01/18/2024 07:47:00 PM
- Das Board of Directors von Sinovac lehnt einstimmig ein unaufgefordert abgegebenes Teilkaufangebot ab • Business Wire • 01/18/2024 06:33:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 01/18/2024 12:13:31 PM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 01/18/2024 12:00:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 01/08/2024 09:46:34 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/04/2023 11:01:59 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/03/2023 01:39:57 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/15/2023 12:59:40 PM
- シノバック、新型コロナウイルスに対するSA55抗体注射剤の臨床試験について進展を報告 • Business Wire • 09/12/2023 10:10:00 AM
- SINOVAC rend compte des progrès réalisés dans le cadre de son essai clinique concernant l’injection anti-COVID-19 à base d’anticorps SA55 • Business Wire • 09/11/2023 02:36:00 PM
- SINOVAC informiert über die Fortschritte bei der klinischen Studie für den Anti-COVID-19-Antikörper SA55 Injection • Business Wire • 09/11/2023 02:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 10:16:45 AM
- SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection • Business Wire • 09/11/2023 09:55:00 AM
- シノバック取締役会、同意なき株式の部分公開買付を全会一致で拒否 • Business Wire • 09/06/2023 11:35:00 AM
- Sinovac-Vorstand lehnt ein unangefordertes Teilübernahmeangebot einstimmig ab • Business Wire • 09/05/2023 04:16:00 PM
- Le conseil d’administration de Sinovac rejette à l’unanimité une offre publique d’achat partielle non sollicitée • Business Wire • 09/05/2023 03:36:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 09/05/2023 11:04:01 AM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 09/05/2023 08:12:00 AM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM